25-Sep-2026
Globe Newswire (Tue, 8-Sep 9:15 AM ET)
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Globe Newswire (Thu, 27-Aug 9:01 AM ET)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
ACCESS Newswire (Thu, 27-Aug 9:01 AM ET)
Globe Newswire (Tue, 18-Aug 8:53 AM ET)
Globe Newswire (Thu, 13-Aug 4:15 PM ET)
Globe Newswire (Tue, 4-Aug 8:50 AM ET)
Globe Newswire (Wed, 22-Jul 8:40 AM ET)
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Globe Newswire (Tue, 21-Jul 7:05 AM ET)
Globe Newswire (Tue, 7-Jul 8:55 AM ET)
Globe Newswire (Mon, 29-Jun 8:45 AM ET)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of September 25, 2026, AKTX stock price declined to $9.76 with 70,821 million shares trading.
AKTX has a beta of 3.07, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.03 to the broad based SPY ETF.
AKTX has a market cap of $18.99 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AKTX traded as high as $176.00 and as low as $3.02.
AKTX has underperformed the market in the last year with a price return of -78.2% while the SPY ETF gained +18.4%. AKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.5% and -13.7%, respectively, while the SPY returned +5.3% and +1.2%, respectively.
AKTX support price is $9.20 and resistance is $10.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.